Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (LIPO) (“Lipella,” “our,” “us” or the “Company”), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback